Hawaii 2023 Regular Session

Hawaii House Bill HB70

Introduced
1/19/23  
Refer
1/25/23  
Refer
1/30/23  
Report Pass
2/17/23  
Refer
2/17/23  
Report Pass
3/3/23  
Engrossed
3/7/23  
Refer
3/10/23  

Caption

Relating To Controlled Substances.

Impact

If enacted, this bill would have a significant impact on the state's regulation of hemp products and controlled substances. By adding specific cannabinoids to the list of Schedule I controlled substances, the bill seeks to enhance the state’s regulatory framework around substances that are deemed potentially harmful or misused. This change reflects a growing concern over synthetic cannabinoids and their effects on public health and safety, particularly in a market that increasingly includes various hemp-derived products.

Summary

House Bill 70 aims to amend the existing laws relating to controlled substances in Hawaii, specifically addressing the sale and distribution of hemp products that contain certain cannabinoids. The proposed legislation prohibits the sale, holding, offering, or distribution of hemp products that contain cannabinoids created through isomerization, such as Delta 6 and Delta 8 tetrahydrocannabinol. However, it makes a notable exception for medical cannabis dispensaries, allowing them to sell products that contain naturally-occurring Delta 8 tetrahydrocannabinol.

Sentiment

The sentiment surrounding HB 70 appears to be mixed. Supporters of the bill might argue that it is a necessary measure to protect consumers and maintain public health standards by regulating the market for hemp products. However, there may also be concerns from businesses and consumers who feel that such regulations could limit access to lesser-known but beneficial hemp derivatives, highlighting the tension between regulation and market freedom.

Contention

Notable points of contention around this bill include debates on the adequacy of the proposed regulatory framework to distinguish between harmful synthetic cannabinoids and harmless natural variants. Critics may express concerns that the bill's broad language could inadvertently encompass products that should not be restricted, impacting patients and consumers who rely on these products for medical purposes. The balance between necessary regulation and consumer access will likely be a focal point in the discussions surrounding the bill.

Companion Bills

No companion bills found.

Similar Bills

HI HB70

Relating To Controlled Substances.

HI HB1886

Relating To Controlled Substances.

HI HB1482

Related To Controlled Substances.

HI HB422

Relating To Controlled Substances.

HI HB1097

Relating To The Uniform Controlled Substances Act.

HI SB1186

Relating To The Uniform Controlled Substances Act.

IN SB0209

Drug schedules.

HI SB3141

Relating To The Uniform Controlled Substances Act.